Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q4 2016 · 10-K
Revenue$376.00K$376.00K−88.3% vs Q4 2015 Net Income-$6.00M-$6.00MN/M vs Q4 2015 EPS Diluted-$0.34-$0.34N/M vs Q4 2015 Operating Income-$5,462,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,698,000N/M Margins · derivedOperating margin-1452.7%−1372.0 pt vs Q4 2015
Net margin-1596.8%−1474.8 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 8, 2017 · 67 d after period end